ArticleBlood advances2020
The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation.
Article in Blood advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Serum vitamin d levels predict hospital-free days in outpatient allogeneic stem cell transplantation survivors: implications for long-term health outcomes.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Article
- Assessing Quality of Life and Symptoms in Transplantation and CAR-T Recipients: Expert Panel Recommendations from the Survivorship Special Interest Group of ASTCT.Transplantation and cellular therapy · 2025Review
- The Predictive Power of the Transplant Evaluation Rating Scale (TERS) for Psychosocial Outcomes in Living-Donor Kidney Transplant Recipients: A Two-Year Prospective Study.Journal of clinical medicine · 2024Article
- Disparities in access to hematopoietic cell transplant persist at a transplant center.Bone marrow transplantation · 2024Article
- The sum of the parts: what we can and cannot learn from comorbidity scores in allogeneic transplantation.Hematology. American Society of Hematology. Education Program · 2023Review
- Psychosocial assessment practices for hematopoietic stem cell transplantation: a national survey study.Bone marrow transplantation · 2023Article
- Weight loss post-allogeneic stem cell transplant is associated with increased transplant-related mortality.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Article
- Psychosocial Assessment Practices for Hematopoietic Stem Cell Transplantation: A National Survey Study.Research square · 2023Article
- Psychosocial and financial issues after hematopoietic cell transplantation.Hematology. American Society of Hematology. Education Program · 2021Article
- Increasing access to allotransplants in the United States: the impact of race, geography, and socioeconomics.Hematology. American Society of Hematology. Education Program · 2021Review
- The Transplant Evaluation Rating Scale Predicts Clinical Outcomes 1 Year After Lung Transplantation: A Prospective Longitudinal Study.Frontiers in psychiatry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the impact of psychosocial risks on post-hematopoietic stem cell transplantation (HSCT) outcomes, we prospectively conducted psychosocial assessment of 556 consecutive allogeneic HSCT patients who received their first allogeneic transplant at our center between 2003 and 2017. The Transplant Evaluation Rating Scale (TERS) score was prospectively assessed by a psychologist before transplantation, and patients were categorized as low, intermediate, or high risk based on their TERS score. Patients in the high-risk TERS group had significantly longer hospital stays during the first 180 days and 1 year post-allogeneic HSCT compared with the low-risk group (16 vs 13 and 21 vs 16 days; P = .05 and .02, respectively). The survival estimates for low-, intermediate-, and high-risk TERS groups at 3 year were as follows: overall survival (OS), 73%, 60%, and 65%; disease-free survival (DFS), 63%, 55%, and 60%; nonrelapse mortality (NRM), 11%, 20%, and 17%; and relapse, 26%, 25%, and 23%, respectively. In a multivariable analysis, intermediate- and high-risk TERS scores predicted for inferior OS, similar DFS, and higher NRM compared with low-risk TERS score. In a subset analysis of patients with low/intermediate risk per Disease Risk Index, multivariable analysis showed that high- and intermediate-risk TERS scores predicted for significantly worse OS, worse DFS, higher NRM, and similar relapse rates compared with low-risk TERS score. Our findings show that psychosocial factors as measured by TERS score are strong predictors of morbidity and mortality after HSCT among patients with low/intermediate disease risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.